Malt worker's lung

disease
On this page

Also known as alveolitis due to aspergillus clavatusAspergillus caused extrinsic allergic alveolitisAspergillus extrinsic allergic alveolitismalt workers lungMalt workers' lung

Summary

Malt worker’s lung (MONDO:0002266) is a disease. A subtype of pulmonary aspergilloma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namemalt worker’s lung
Mondo IDMONDO:0002266
DOIDDOID:2314
SNOMED CT25897000
UMLSC0155888
MedGen510125
GARD0023103
Is cancer (heuristic)no

Also known as: alveolitis due to aspergillus clavatus · Aspergillus caused extrinsic allergic alveolitis · Aspergillus extrinsic allergic alveolitis · malt workers lung · Malt workers’ lung

Disease family

This is a subtype of pulmonary aspergilloma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseasefungal infectious diseaseopportunistic mycosisaspergillosispulmonary aspergillomamalt worker’s lung

Related subtypes (1): invasive aspergillosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.